Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

1.3K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.3K
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

539
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
539
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

4.4K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.4K
Mitral Regurgitation I: Introduction01:20

Mitral Regurgitation I: Introduction

863
Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
863
Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

1.1K
Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
1.1K
Mitral Stenosis II: Clinical features and Diagnostic Tests01:23

Mitral Stenosis II: Clinical features and Diagnostic Tests

387
Mitral stenosis is a heart condition in which the mitral valve, which allows blood to flow from the left atrium to the left ventricle, becomes narrowed or stenotic. This narrowing hinders blood flow and leads to clinical symptoms requiring specific medical evaluations and management strategies. The following overview outlines the clinical symptoms, assessments, diagnostic findings, prevention methods, and treatments for mitral stenosis.Clinical ManifestationsDyspnea (shortness of breath): This...
387

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Microbial carbonate biomineralization in the deep subsurface biosphere: Decoding long-term carbon sequestration potential and methanogenesis risk.

Journal of environmental management·2026
Same author

Participant lived experiences of high-intensity interval training in UK cardiac rehabilitation (HIIT or MISS UK): A qualitative study.

PloS one·2026
Same author

Voice recognition as an innovative method to identify and monitor heart failure - a review.

Heart failure reviews·2026
Same author

<i>Staphylococcus lugdunensis</i> endocarditis presenting with P wave asystole, valvular destruction and spontaneous closure of an acquired Gerbode defect.

BMJ case reports·2026
Same author

Advanced Clinical Practitioner-led Palliative Care Heart Failure Model within the National Health Service: A Prospective Study of Patient Experience, Healthcare Costs and End-of-life Outcomes.

European journal of cardiovascular nursing·2026
Same author

Unmasking inequalities in gastrointestinal cancer outcomes among Asian American subpopulations.

Scientific reports·2026

Related Experiment Video

Updated: Mar 17, 2026

Quantification of Global Diastolic Function by Kinematic Modeling-based Analysis of Transmitral Flow via the Parametrized Diastolic Filling Formalism
11:04

Quantification of Global Diastolic Function by Kinematic Modeling-based Analysis of Transmitral Flow via the Parametrized Diastolic Filling Formalism

Published on: September 1, 2014

11.6K

Does left ventricular diastolic dysfunction progress through stages? Insights from a community heart failure study.

Prithwish Banerjee1, Aamir Motiwala2, Hanif Muhammad Mustafa3

  • 1Warwick Medical School, Gibbet Hill Road, Coventry CV4 7AL, United Kingdom; Department of Cardiology, University Hospital Coventry and Warwickshire, Coventry CV2 2DX, United Kingdom.

International Journal of Cardiology
|July 20, 2016
PubMed
Summary

Patients in the pre-heart failure with preserved ejection fraction (HFpEF) stage experienced numerous clinical events. Elevated E/e

Keywords:
Community heart failure clinicComorbiditiesHFPEFHospital admissionsMortality

More Related Videos

Murine Echocardiography of Left Atrium, Aorta, and Pulmonary Artery
08:17

Murine Echocardiography of Left Atrium, Aorta, and Pulmonary Artery

Published on: February 20, 2017

15.1K
Noninvasive Determination of Vortex Formation Time Using Transesophageal Echocardiography During Cardiac Surgery
04:48

Noninvasive Determination of Vortex Formation Time Using Transesophageal Echocardiography During Cardiac Surgery

Published on: November 28, 2018

8.4K

Related Experiment Videos

Last Updated: Mar 17, 2026

Quantification of Global Diastolic Function by Kinematic Modeling-based Analysis of Transmitral Flow via the Parametrized Diastolic Filling Formalism
11:04

Quantification of Global Diastolic Function by Kinematic Modeling-based Analysis of Transmitral Flow via the Parametrized Diastolic Filling Formalism

Published on: September 1, 2014

11.6K
Murine Echocardiography of Left Atrium, Aorta, and Pulmonary Artery
08:17

Murine Echocardiography of Left Atrium, Aorta, and Pulmonary Artery

Published on: February 20, 2017

15.1K
Noninvasive Determination of Vortex Formation Time Using Transesophageal Echocardiography During Cardiac Surgery
04:48

Noninvasive Determination of Vortex Formation Time Using Transesophageal Echocardiography During Cardiac Surgery

Published on: November 28, 2018

8.4K

Area of Science:

  • Cardiology
  • Heart Failure Research

Background:

  • Investigated symptomatic patients with left ventricular diastolic dysfunction (LVDD) and elevated biomarkers but no overt heart failure.
  • Hypothesized these patients represent a pre-heart failure with preserved ejection fraction (HFpEF) stage.

Purpose of the Study:

  • To evaluate clinical outcomes in patients suspected of being in the pre-HFpEF stage.
  • To compare 1-year event rates based on E/e' ratio, a marker of diastolic dysfunction severity.

Main Methods:

  • Retrospective pilot study including 80 patients with LVDD and LVEF >45%.
  • Patients divided into two groups: E/e' <15 and E/e' ≥15, reflecting rising and raised LV end-diastolic pressure.
  • 1-year follow-up assessing all-cause and cardiovascular events (deaths, hospital admissions).

Main Results:

  • The group with E/e' ≥15 showed significantly higher 1-year all-cause events (p=0.03).
  • Overall, 45 clinical events occurred in the cohort within 12 months, including 39 hospital admissions and 6 deaths.
  • 20 of the total 45 events were cardiovascular.

Conclusions:

  • Patients in the hypothesized pre-HFpEF stage experienced a high event burden.
  • Elevated E/e' (≥15) was associated with poor 1-year outcomes, influenced by comorbidities.
  • Close monitoring and aggressive comorbidity management are recommended for these patients in dedicated HFpEF clinics.